Posted by Michael Wonder on 09 Nov 2022
Mitsubishi Tanabe Pharma Canada announces Canadian authorisation of Radicava (edarvarone) oral suspension for the treatment of patients with ALS
8 November 2022 - Comprehensive clinical development program for edaravone in ALS has spanned over a decade and included multiple clinical trials for IV and oral formulations.
Mitsubishi Tanabe Pharma Canada today announced that Health Canada has granted market authorisation for Radicava oral suspension, the oral formulation of Radicava IV (edaravone), for the treatment of patients with amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, a neurodegenerative disease that currently has no cure and can progress rapidly.
